The table below shows Kymera Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$34.37M
$2.76M
$11.48M
$22.10M
$3.74M
$25.65M
Cost of revenue
$34.37M
$2.76M
$11.48M
$22.10M
$3.74M
$25.65M
Gross profit
-
-
-
-
-
-
R&D
$98.16M
$74.09M
$78.39M
$80.25M
$60.41M
$59.20M
KYMR annual revenue (10-K history)
Kymera Therapeutics, Inc. reported annual revenue of $39.21M for fiscal year 2025. That is down 16.7% from $47.07M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $2.93M (FY 2019) to $39.21M. Figures come from the company's audited annual reports as filed with the SEC.
